Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors

Atherosclerosis. 2022 Nov:361:30-31. doi: 10.1016/j.atherosclerosis.2022.10.010. Epub 2022 Oct 21.

Authors

Maya S Safarova¹, Iftikhar J Kullo²

Affiliations

¹ Department of Cardiovascular Medicine, University of Kansas Hospital and Medical Center, 3901 Rainbow Blvd Kansas City, Kansas, 66160, USA. Electronic address: msafarova@kumc.edu.
² Department of Cardiovascular Medicine and the Gonda Vascular Center, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Electronic address: Kullo.Iftikhar@mayo.edu.

PMID: 36344291
DOI: 10.1016/j.atherosclerosis.2022.10.010

No abstract available

Keywords: ASCVD; LDL; Lipoprotein(a); Mendelian randomization; PCSK9 inhibitors; Residual risk.

Publication types

Editorial
Comment

MeSH terms

Anticholesteremic Agents* / therapeutic use
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Heart Disease Risk Factors
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Lipoprotein(a)
PCSK9 Inhibitors
Proprotein Convertase 9
Risk Factors

Substances

PCSK9 Inhibitors
Lipoprotein(a)
PCSK9 protein, human
Proprotein Convertase 9
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors